Literature DB >> 23198569

[Pediatric nonalcoholic fatty liver disease/nonalcoholic steatohepatitis].

Yoshihisa Takahashi1, Toshio Fukusato, Ayano Inui, Tomoo Fujisawa.   

Abstract

Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is a hepatic disease associated with metabolic syndrome. In recent years, pediatric NAFLD has increased in line with the increased prevalence of pediatric obesity. The estimated prevalence of pediatric NAFLD is 2.6-9.6%. With regard to the pathogenesis of NAFLD/ NASH, the "two-hit" or "multiple-hit" hypothesis is widely accepted, and many genetic and environmental factors are associated with the development of NAFLD/NASH. Liver biopsy is regarded as the gold standard for the diagnosis of NAFLD/NASH. Pediatric NAFLD has different histopathological characteristics from those of adult NAFLD. Although pharmacotherapy has been studied in clinical trials, lifestyle modification by diet and exercise remains the mainstay of treatment for NAFLD/NASH.

Entities:  

Mesh:

Year:  2012        PMID: 23198569

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  4 in total

Review 1.  The Role of Bariatric Surgery in Abdominal Organ Transplantation-the Next Big Challenge?

Authors:  Tomasz Dziodzio; Matthias Biebl; Robert Öllinger; Johann Pratschke; Christian Denecke
Journal:  Obes Surg       Date:  2017-10       Impact factor: 4.129

2.  Profile of Free Fatty Acids and Fractions of Phospholipids, Cholesterol Esters and Triglycerides in Serum of Obese Youth with and without Metabolic Syndrome.

Authors:  Juliana Bermúdez-Cardona; Claudia Velásquez-Rodríguez
Journal:  Nutrients       Date:  2016-02-15       Impact factor: 5.717

3.  Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism.

Authors:  Xin Qiao; Zhuo-Chao Zhou; Rui Niu; Yu-Tong Su; Yue Sun; Hong-Lei Liu; Jia-Lin Teng; Jun-Na Ye; Hui Shi; Cheng-De Yang; Xiao-Bing Cheng
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

4.  PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease.

Authors:  Quelson Coelho Lisboa; Mateus Jorge Nardelli; Patrícia de Araújo Pereira; Débora Marques Miranda; Stephanie Nunes Ribeiro; Raissa Soares Neves Costa; Camila Azevedo Versiani; Paula Vieira Teixeira Vidigal; Teresa Cristina de Abreu Ferrari; Claudia Alves Couto
Journal:  World J Hepatol       Date:  2020-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.